Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04294862 · ClinicalTrials.gov registry record · Phase 1
Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty
A Phase 1 study of Prosthetic-joint Infection, sponsored by TenNor Therapeutics Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT04294862: Completed Phase 1 study of Prosthetic-joint Infection, sponsored by TenNor Therapeutics Limited.
NCT04294862 is a Phase 1 study of Prosthetic-joint Infection that has completed, run by TenNor Therapeutics Limited. The registered enrollment target is 13 participants, below the 97-participant average among 9 other Prosthetic-joint Infection trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04294862, a Phase 1 study of Prosthetic-joint Infection, has completed, sponsored by TenNor Therapeutics Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will investigate TNP-2092 distribution into joint tissues in participants undergoing a total hip arthroplasty (THA) or a total knee arthroplasty (TKA). Tissue distribution is the primary objective, and plasma pharmacokinetics (PK), safety, and tolerability are secondary objectives.
Primary Outcome
Concentration in ng/mL
Conditions Studied
Interventions
- DRUG TNP-2092
Study Locations (1)
Pennsylvania
- Rothman Orthopedic Institute - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2022-06-29 |
| Phase | Phase 1 |
What the finished NCT04294862 record still lists
NCT04294862 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 97-participant average among 9 other Prosthetic-joint Infection trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Prosthetic-joint Infection appearing as the primary indexed condition, and to 1 intervention - of which TNP-2092 is the first listed.
NCT04294862 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04294862 about?
NCT04294862 is a clinical study titled "Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty". This study will investigate TNP-2092 distribution into joint tissues in participants undergoing a total hip arthroplasty (THA) or a total knee arthroplasty (TKA). Tissue distribution is the primary objective, and plasma pharmacokinetics (PK), safety, and tolerability are secondary objectives.
What is the current status of trial NCT04294862?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2021-03-01. Estimated completion is 2022-06-29.
What conditions does trial NCT04294862 study?
This clinical trial studies the following conditions: Prosthetic-joint Infection.
What interventions are being tested in trial NCT04294862?
The interventions under investigation include: TNP-2092 (DRUG).
Who is sponsoring clinical trial NCT04294862?
This trial is sponsored by TenNor Therapeutics Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04294862 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prosthetic-joint Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04294862's enrollment target sits among peer trials
13 10th of 9 the lowest of 9 other Prosthetic-joint Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prosthetic-joint Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effect of Peri-Operative Adjunctive Probiotics on Immunological Markers in Cases of Prosthetic Joint Infection of the Hip and Knee
RECRUITING · NA
-
Real-component Vs All-cement Articulating Spacers for Periprosthetic Knee Infection
RECRUITING · NA
-
Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty
RECRUITING · Phase 2
-
Reduction of Bacterial Seeding in Total Shoulder Arthroplasty
RECRUITING · NA
-
A Second Trial of the Abbreviated Protocol Two-Stage Exchange
COMPLETED · Phase 2
-
SURGX Antimicrobial Gel Versus Povidone-iodine Skin Incision Prep in Total Shoulder Arthroplasty
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI